Assessment of Overall Survival in Glioma Patients as Predicted by Metabolomic Criteria

We assess the efficacy of the metabolomic profile from glioma biopsies in providing estimates of postsurgical Overall Survival in glioma patients.

Autores: María L. Gandía-González - Sebastián Cerdán - Laura Barrios - Pilar López-Larrubia - Pablo G. Feijoó - Alexis Palpan Jr. - José M. Roda - Juan Solivera

Abstract: Tumor biopsies from 46 patients bearing gliomas, obtained neurosurgically in the period 1992–1998, were analyzed by high resolution 1H magnetic resonance spectroscopy (HR- 1H MRS), following retrospectively individual postsurgical Overall Survival up to 720 weeks.

The Overall Survival profile could be resolved in three groups; Short (shorter than 52 weeks, n = 19), Intermediate (between 53 and 364 weeks, n = 19) or Long (longer than 365 weeks, n = 8), respectively. Classical histopathological analysis assigned WHO grades II–IV to every biopsy but notably, some patients with low grade glioma depicted unexpectedly Short Overall Survival, while some patients with high grade glioma, presented unpredictably Long Overall Survival. To explore the reasons underlying these different responses, we analyzed HR-1H MRS spectra from acid extracts of the same biopsies

Leer Documento PDF

Parada et al 2019 British Journal of Pharmacology

Inflammation takes place in both chronic and acute brain diseases and plays a key role in the development of several pathologies.

Autores: Esther Parada - Ana I. Casas - Alejandra Palomino‐Antolin - Vanessa Gómez‐Rangel - Alfonso Rubio‐Navarro - Victor Farré‐Alins - Paloma Narros‐Fernandez - Melania Guerrero‐Hue - Juan Antonio Moreno - Juliana M. Rosa - J.M. Roda - Borja J. Hernández‐García - Javier Egea

Abstract: Indeed, immune activation in the CNS is a common feature of brain injuries such as stroke, neurodegenerative diseases, and multiple sclerosis. Chronic inflammation leads to noxious effects on neurons and, thus,contributes to the pathophysiology of neurodegenerative diseases.Brain ischaemia is an acute injury that leads to the production of ROS and reactive nitrogen species (RNS), lipid peroxidation, blood–brain barrier (BBB) disruption, and exacerbated inflammation resultingin dramatic neuronal death ...

Leer Documento PDF

Paralisis facial

Parálisis facial: guía de práctica clínica de la Sociedad Española de ORL.

Autores: Luis Lassaletta - José Manuel Morales-Puebla - Xabier Altuna - Álvaro Arbizu - Miguel Arístegui - Ángel Batuecas - Carlos Cenjor - Juan Manuel Espinosa-Sánchez - Leire García-Iza - Pilar García-Raya - Teresa González-Otero - Manuel Mañós - Carlos Martín - Susana Moraleda - Jose Maria Roda - Susana Santiago - Jesús Benítez - Laura Cavallé - Victor Correia - Jose Manuel Estévez - Justo Gómez - Rocío González - Jorge Jiménez - Jose Luis Lacosta - María José Lavilla - Julio Peñarrocha - Rubén Polo - Francisco García-Purriños - Francisco Ramos - Manuel Tomás - María Uzcanga - Luis Ángel Vallejo - Javier Gavilán

Abstract: La parálisis de Bell es la forma más común de paresia o parálisis facial. Sin embargo,no todos los pacientes con parálisis facial tienen una parálisis de Bell. Otras causas frecuentes incluyen las secuelas del tratamiento del neurinoma del viiipar, el cáncer de cabeza y cuello, la iatrogenia, el zósterótico y los traumatismos. El abordaje de cada una de estas situaciones es totalmente diferente. El objetivo de esta guía es servir de consej opara el tratamiento y el seguimiento de los pacientes con parálisis facial. Nuestra idea es que la guía sea práctica, haciendo hincapié en recomendaciones efectivas y útiles en el manejo diario de los pacientes.

Leer Documento PDF